Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Table 2

Updated phase III randomised trials on hypofractionation for prostate cancer. All results are statistically significant, except those marked with n.s.

		Median FU (yrs)	Dose (Gy); per fraction	Benefit bDFS (%)	Toxicity; Gr2 GI (%)	Toxicity; Gr2 GU (%)
Dutch trial
Aluwini et al. 2015	820	5	39 × 2 versus 19 × 3.4	77 versus 80	Equal; 13	22 versus 23
RTOG 0415
Lee et al. 2016	1092	5.8	41 × 1.8 versus 28 × 2.5	85.3 versus 86.3	11.4 versus 18.3	20.5 versus 26.2
CHHiP
Dearnaley et al. 2016	3163	5.1	37 × 2 versus 20 × 3 versus 19 × 3	88.3 versus 90.6 versus 85.9	Equal; 2	11 versus 13

bDFS: biochemical disease-free survival; CHHiP: conventional or hypofractionated high dose intensity modulated radiotherapy in prostate cancer; n.s.: not significant; Gr2: grade 2 or more toxicity.